急性呼吸窘迫综合征
先天免疫系统
地塞米松
免疫学
干扰素
免疫系统
生物
炎症
医学
肺
内科学
作者
Sarthak Sinha,Nicole L. Rosin,Rohit Arora,Elodie Labit,Arzina Jaffer,Leslie Cao,Raquel Farias,Angela Nguyen,Luiz G. Almeida,Antoine Dufour,Amy Bromley,Braedon McDonald,Mark R. Gillrie,Marvin J. Fritzler,Bryan G. Yipp,Jeff Biernaskie
出处
期刊:Nature Medicine
[Springer Nature]
日期:2021-11-15
卷期号:28 (1): 201-211
被引量:164
标识
DOI:10.1038/s41591-021-01576-3
摘要
Abstract Although critical for host defense, innate immune cells are also pathologic drivers of acute respiratory distress syndrome (ARDS). Innate immune dynamics during Coronavirus Disease 2019 (COVID-19) ARDS, compared to ARDS from other respiratory pathogens, is unclear. Moreover, mechanisms underlying the beneficial effects of dexamethasone during severe COVID-19 remain elusive. Using single-cell RNA sequencing and plasma proteomics, we discovered that, compared to bacterial ARDS, COVID-19 was associated with expansion of distinct neutrophil states characterized by interferon (IFN) and prostaglandin signaling. Dexamethasone during severe COVID-19 affected circulating neutrophils, altered IFN active neutrophils, downregulated interferon-stimulated genes and activated IL-1R2 + neutrophils. Dexamethasone also expanded immunosuppressive immature neutrophils and remodeled cellular interactions by changing neutrophils from information receivers into information providers. Male patients had higher proportions of IFN active neutrophils and preferential steroid-induced immature neutrophil expansion, potentially affecting outcomes. Our single-cell atlas (see ‘Data availability’ section) defines COVID-19-enriched neutrophil states and molecular mechanisms of dexamethasone action to develop targeted immunotherapies for severe COVID-19.
科研通智能强力驱动
Strongly Powered by AbleSci AI